Gene clues may predict cancer drug success
NCT ID NCT01827956
First seen Jan 11, 2026 · Last updated May 03, 2026 · Updated 13 times
Summary
This study explored whether small differences in a person's genes (called FCGR polymorphisms) can predict how well the drug cetuximab works for advanced head and neck cancers. Researchers analyzed blood samples from 121 patients to look for these gene variations and see if they were linked to treatment outcomes. The goal was to find a way to personalize treatment, not to test a new cure or therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER GINGIVAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Bergonié
Bordeaux, Aquitaine, 33000, France
Conditions
Explore the condition pages connected to this study.